NCT04635605View on ClinicalTrials.gov

Methylene Blue Treatment of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

August 13, 2021

Study Completion Date

August 13, 2021

Conditions
SARS-CoV2
Interventions
DRUG

Methylene Blue

Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.

DRUG

Control Test

Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.

Trial Locations (1)

6900

Fondazione Epatocentro Ticino, Lugano

All Listed Sponsors
lead

Fondazione Epatocentro Ticino

OTHER

NCT04635605 - Methylene Blue Treatment of COVID-19 | Biotech Hunter | Biotech Hunter